» Articles » PMID: 35740085

Selenium and Selenoproteins at the Intersection of Type 2 Diabetes and Thyroid Pathophysiology

Overview
Date 2022 Jun 24
PMID 35740085
Authors
Affiliations
Soon will be listed here.
Abstract

Type 2 diabetes (T2D) is considered one of the largest global public-health concerns, affecting approximately more than 400 million individuals worldwide. The pathogenesis of T2D is very complex and, among the modifiable risk factors, selenium (Se) has recently emerged as a determinant of T2D pathogenesis and progression. Selenium is considered an essential element with antioxidant properties, and is incorporated into the selenoproteins involved in the antioxidant response. Furthermore, deiodinases, the enzymes responsible for homeostasis and for controlling the activity of thyroid hormones (THs), contain Se. Given the crucial action of oxidative stress in the onset of insulin resistance (IR) and T2D, and the close connection between THs and glucose metabolism, Se may be involved in these fundamental relationships; it may cover a dual role, both as a protective factor and as a risk factor of T2D, depending on its basal plasma concentration and the individual's diet intake. In this review we discuss the current evidence (from experimental, observational and randomized clinical studies) on how Se is associated with the occurrence of T2D and its influence on the relationship between thyroid pathophysiology, IR and T2D.

Citing Articles

Vitamin C in the Management of Thyroid Cancer: A Highway to New Treatment?.

Gorini F, Tonacci A Antioxidants (Basel). 2024; 13(10).

PMID: 39456495 PMC: 11505632. DOI: 10.3390/antiox13101242.


Metabolic Syndrome, Thyroid Dysfunction, and Cardiovascular Risk: The Triptych of Evil.

Pingitore A, Gaggini M, Mastorci F, Sabatino L, Cordiviola L, Vassalle C Int J Mol Sci. 2024; 25(19).

PMID: 39408957 PMC: 11477096. DOI: 10.3390/ijms251910628.


Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic Therapy.

Cesca B, Caverzan M, Lamberti M, Ibarra L Int J Mol Sci. 2024; 25(14).

PMID: 39062770 PMC: 11277534. DOI: 10.3390/ijms25147525.


Vitamin D, selenium in type 2 diabetes and Hashimoto's thyroiditis: Is it effective?.

Sugunakar Reddy K, Jain V, Varatharajan S, Pallavali J World J Diabetes. 2024; 15(5):1048-1050.

PMID: 38766428 PMC: 11099363. DOI: 10.4239/wjd.v15.i5.1048.


The Regulation of Selenoproteins in Diabetes: A New Way to Treat Diabetes.

Liang J, He Y, Huang C, Ji F, Zhou X, Yin Y Curr Pharm Des. 2024; 30(20):1541-1547.

PMID: 38706350 DOI: 10.2174/0113816128302667240422110226.


References
1.
Zhou J, Huang K, Lei X . Selenium and diabetes--evidence from animal studies. Free Radic Biol Med. 2013; 65:1548-1556. PMC: 3859733. DOI: 10.1016/j.freeradbiomed.2013.07.012. View

2.
Kaneto H, Matsuoka T . Involvement of oxidative stress in suppression of insulin biosynthesis under diabetic conditions. Int J Mol Sci. 2012; 13(10):13680-90. PMC: 3497347. DOI: 10.3390/ijms131013680. View

3.
Aziz F, Alhazmi A, Aljameil N, Mahmood I, Tabassum H, Mushfiq S . Serum Selenium and Lead Levels: a Possible Link with Diabetes and Associated Proteinuria. Biol Trace Elem Res. 2019; 193(2):342-347. DOI: 10.1007/s12011-019-01721-7. View

4.
Yang S, Hwang S, Choi H, Yoo H, Seo J, Kim S . Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrinol Metab. 2011; 96(8):E1325-9. DOI: 10.1210/jc.2011-0620. View

5.
Jackson M, Cao J, Zeng H, Uthus E, Combs Jr G . S-adenosylmethionine-dependent protein methylation is required for expression of selenoprotein P and gluconeogenic enzymes in HepG2 human hepatocytes. J Biol Chem. 2012; 287(43):36455-64. PMC: 3476311. DOI: 10.1074/jbc.M112.412932. View